Acceleron Pharma Inc Net debt/EBITDA
Mi az Acceleron Pharma Inc Net debt/EBITDA?
A Net debt/EBITDA az Acceleron Pharma Inc - 10.60
Mi a Net debt/EBITDA meghatározása?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA a Health Care szektor a NASDAQ-on cégekben a Acceleron Pharma Inc -hoz képest
Mit csinál Acceleron Pharma Inc?
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
net debt/ebitda -hoz hasonló cégek Acceleron Pharma Inc
- GGL Resources nak Net debt/EBITDA 10.59 van
- T-Mobile US nak Net debt/EBITDA 10.59 van
- WorleyParsons nak Net debt/EBITDA 10.59 van
- WorleyParsons nak Net debt/EBITDA 10.59 van
- Colfax Corp nak Net debt/EBITDA 10.59 van
- The Cooper Companies nak Net debt/EBITDA 10.59 van
- Acceleron Pharma Inc nak Net debt/EBITDA 10.60 van
- Faurecia S.E nak Net debt/EBITDA 10.60 van
- Kellogg nak Net debt/EBITDA 10.61 van
- Saputo nak Net debt/EBITDA 10.61 van
- Aon plc nak Net debt/EBITDA 10.62 van
- Olema Pharmaceuticals nak Net debt/EBITDA 10.62 van
- RealPage nak Net debt/EBITDA 10.63 van